{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:10:06Z","timestamp":1790471406798,"version":"4.1.0"},"reference-count":151,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the most severe health crisis, causing extraordinary economic disruption worldwide. SARS-CoV-2 is a single-stranded RNA-enveloped virus. The process of viral replication and particle packaging is finished in host cells. Viral proteins, including both structural and nonstructural proteins, play important roles in the viral life cycle, which also provides the targets of treatment. Therefore, a better understanding of the structural function of virus proteins is crucial to speed up the development of vaccines and therapeutic strategies. Currently, the structure and function of proteins encoded by the SARS-CoV-2 genome are reviewed by several studies. However, most of them are based on the analysis of SARS-CoV-1 particles, lacking a systematic review update for SARS-CoV-2. Here, we specifically focus on the structure and function of proteins encoded by SARS-CoV-2. Viral proteins that contribute to COVID-19 infection and disease pathogenesis are reviewed according to the most recent research findings. The structure-function correlation of viral proteins provides a fundamental rationale for vaccine development and targeted therapy. Then, current antiviral vaccines are updated, such as inactive viral vaccines and protein-based vaccines and DNA, mRNA, and circular RNA vaccines. A summary of other therapeutic options is also reviewed, including monoclonal antibodies such as a cross-neutralizer antibody, a constructed cobinding antibody, a dual functional monoclonal antibody, an antibody cocktail, and an engineered bispecific antibody, as well as peptide-based inhibitors, chemical compounds, and clustered regularly interspaced short palindromic repeats (CRISPR) exploration. Overall, viral proteins and their functions provide the basis for targeted therapy and vaccine development.<\/jats:p>","DOI":"10.3390\/ijms23116083","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:50:51Z","timestamp":1653814251000},"page":"6083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2567-029X","authenticated-orcid":false,"given":"Chunye","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-5864","authenticated-orcid":false,"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 5, 536\u2013544.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","article-title":"COVID-19 and comorbidities: Deleterious impact on infected patients","volume":"13","author":"Ejaz","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","article-title":"The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections","volume":"15","author":"Machhi","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yadav, R., Chaudhary, J.K., Jain, N., Chaudhary, P.K., Khanra, S., Dhamija, P., Sharma, A., Kumar, A., and Handu, S. (2021). Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells, 10.","DOI":"10.3390\/cells10040821"},{"key":"ref_6","first-page":"3","article-title":"Properties of Coronavirus and SARS-CoV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, Function, and Evolution of Coronavirus Spike Proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Xia, X. (2021). Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses, 13.","DOI":"10.3390\/v13010109"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"152091","DOI":"10.1016\/j.imbio.2021.152091","article-title":"Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development","volume":"226","author":"Dakal","year":"2021","journal-title":"Immunobiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1038\/s41467-021-27325-1","article-title":"Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants","volume":"12","author":"Koehler","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein","volume":"94","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16409","DOI":"10.1039\/D0NR03969A","article-title":"Quantitative determination of mechanical stability in the novel coronavirus spike protein","volume":"12","author":"Moreira","year":"2020","journal-title":"Nanoscale"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/acscentsci.0c01056","article-title":"Beyond Shielding: The Roles of Glycans in SARS-CoV-2 Spike Protein","volume":"6","author":"Casalino","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","article-title":"Controlling the SARS-CoV-2 spike glycoprotein conformation","volume":"27","author":"Henderson","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Barreto-Vieira, D.F., da Silva, M.A.N., de Almeida, A.L.T., Rasinhas, A.D.C., Monteiro, M.E., Miranda, M.D., Motta, F.C., Siqueira, M.M., Girard-Dias, W., and Archanjo, B.S. (2022). SARS-CoV-2: Ultrastructural Characterization of Morphogenesis in an In Vitro System. Viruses, 14.","DOI":"10.3390\/v14020201"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11779322211025876","DOI":"10.1177\/11779322211025876","article-title":"Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinform. Biol. Insights"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4389089","DOI":"10.1155\/2020\/4389089","article-title":"Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?","volume":"2020","author":"Bianchi","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wong, N.A., and Saier, M.H. (2021). The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031308"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.jksus.2020.101335","article-title":"Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species","volume":"33","author":"Alharbi","year":"2021","journal-title":"J. King Saud. Univ. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.20411\/pai.v5i1.377","article-title":"The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET","volume":"5","author":"Thomas","year":"2020","journal-title":"Pathog. Immun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3389\/fmicb.2020.02086","article-title":"Is There a Link Between the Pathogenic Human Coronavirus Envelope Protein and Immunopathology? A Review of the Literature","volume":"11","author":"Schoeman","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1038\/s41467-021-23533-x","article-title":"Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1","volume":"12","author":"Chai","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.genrep.2020.100997","article-title":"Mutational insights into the envelope protein of SARS-CoV-2","volume":"22","author":"Rahman","year":"2021","journal-title":"Gene Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24432","DOI":"10.1038\/s41598-021-04133-7","article-title":"Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein","volume":"11","author":"Yalcinkaya","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"198043","DOI":"10.1016\/j.virusres.2020.198043","article-title":"Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gao, T., Gao, Y., Liu, X., Nie, Z., Sun, H., Lin, K., Peng, H., and Wang, S. (2021). Identification and functional analysis of the SARS-COV-2 nucleocapsid protein. BMC Microbiol., 21.","DOI":"10.1186\/s12866-021-02107-3"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41422-020-00408-2","article-title":"Liquid-liquid phase separation by SARS-CoV-2 nucleocapsid protein and RNA","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1038\/s41467-020-19843-1","article-title":"Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates","volume":"11","author":"Savastano","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.molcel.2020.11.041","article-title":"Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid","volume":"80","author":"Iserman","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41467-021-21953-3","article-title":"The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA","volume":"12","author":"Cubuk","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41421-020-00208-3","article-title":"SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2","volume":"6","author":"Mu","year":"2020","journal-title":"Cell Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"791753","DOI":"10.3389\/fimmu.2021.791753","article-title":"SARS-CoV-2 N Protein Induces Acute Lung Injury in Mice via NF-\u0138B Activation","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bai, Z., Cao, Y., Liu, W., and Li, J. (2021). The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses, 13.","DOI":"10.3390\/v13061115"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shi, M., Wang, L., Fontana, P., Vora, S., Zhang, Y., Fu, T.M., Lieberman, J., and Wu, H. (2020). SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism. bioRxiv.","DOI":"10.1101\/2020.09.18.302901"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1021\/acsinfecdis.0c00500","article-title":"Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies","volume":"6","author":"Davies","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gupta, M., Azumaya, C.M., Moritz, M., Pourmal, S., Diallo, A., Merz, G.E., Jang, G., Bouhaddou, M., Fossati, A., and Brilot, A.F. (2021). CryoEM and AI reveal a structure of SARS-CoV-2 Nsp2, a multifunctional protein involved in key host processes. bioRxiv.","DOI":"10.1101\/2021.05.10.443524"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/22221751.2020.1870414","article-title":"SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): Implications for disease presentation across species","volume":"10","author":"Moustaqil","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Armstrong, L.A., Lange, S.M., Dee Cesare, V., Matthews, S.P., Nirujogi, R.S., Cole, I., Hope, A., Cunningham, F., Toth, R., and Mukherjee, R. (2021). Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253364"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00203-020-01998-6","article-title":"SARS-CoV-2 nucleocapsid and Nsp3 binding: An in silico study","volume":"203","author":"Khan","year":"2021","journal-title":"Arch. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/1040841X.2013.813899","article-title":"The expanding roles of endoplasmic reticulum stress in virus replication and pathogenesis","volume":"41","author":"Li","year":"2015","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e0233521","DOI":"10.1128\/mBio.02335-21","article-title":"SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response","volume":"12","author":"Liu","year":"2021","journal-title":"mBio"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"750969","DOI":"10.3389\/fimmu.2021.750969","article-title":"SARS-CoV-2 Nsp5 Activates NF-\u03baB Pathway by Upregulating SUMOylation of MAVS","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sun, X., Liu, Y., Huang, Z., Xu, W., Hu, W., Yi, L., Liu, Z., Chan, H., Zeng, J., and Liu, X. (2022). SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ., 1\u201315.","DOI":"10.1038\/s41418-021-00916-7"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10007","DOI":"10.1021\/acs.jpclett.0c02765","article-title":"Decoding Asymptomatic COVID-19 Infection and Transmission","volume":"11","author":"Wang","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","article-title":"Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2","volume":"31","author":"Peng","year":"2020","journal-title":"Cell Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2022310118","DOI":"10.1073\/pnas.2022310118","article-title":"Coronavirus replication\u2013transcription complex: Vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit","volume":"118","author":"Slanina","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/nar\/gkab1303","article-title":"Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: Implications for its role in viral genome stability and inhibitor identification","volume":"50","author":"Baddock","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-020-00241-4","article-title":"Crystal structure of SARS-CoV-2 nsp10\/nsp16 2\u2032-O-methylase and its implication on antiviral drug design","volume":"5","author":"Lin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eabe1202","DOI":"10.1126\/scisignal.abe1202","article-title":"High-resolution structures of the SARS-CoV-2 2\u2019-O-methyltransferase reveal strategies for structure-based inhibitor design","volume":"13","author":"Minasov","year":"2020","journal-title":"Sci. Signal."},{"key":"ref_52","unstructured":"Gadhave, K., Kumar, P., Kumar, A., Bhardwaj, T., Garg, N., and Giri, R. (2020). NSP 11 of SARS-CoV-2 is an Intrinsically Disordered Protein. bioRxiv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/s41422-021-00578-7","article-title":"SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation","volume":"31","author":"Xu","year":"2021","journal-title":"Cell Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","article-title":"Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex","volume":"182","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543776.2021.1884224","article-title":"Coronavirus helicases: Attractive and unique targets of antiviral drug-development and therapeutic patents","volume":"31","author":"Spratt","year":"2021","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2017.12.024","article-title":"An \u201cOld\u201d protein with a new story: Coronavirus endoribonuclease is important for evading host antiviral defenses","volume":"517","author":"Deng","year":"2018","journal-title":"Virology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1073\/pnas.1921485117","article-title":"Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors","volume":"117","author":"Hackbart","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0040221","DOI":"10.1128\/JVI.00402-21","article-title":"Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice","volume":"95","author":"Silvas","year":"2021","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13464","DOI":"10.1038\/s41598-021-92941-2","article-title":"Activation of NF-\u03baB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2","volume":"11","author":"Su","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2021785118","DOI":"10.1073\/pnas.2021785118","article-title":"Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein","volume":"118","author":"Flower","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0264-410X(95)00211-I","article-title":"Inactivated poliovirus vaccine: Past and present experience","volume":"14","author":"Murdin","year":"1996","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: What you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated Virus and Protein-Based COVID-19 Vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"taab051","DOI":"10.1093\/jtm\/taab051","article-title":"Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2","volume":"28","author":"Sapkal","year":"2021","journal-title":"J. Travel Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","article-title":"Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: A test-negative, case-control study","volume":"22","author":"Desai","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_69","unstructured":"WHO (2021). Status of COVID-19 Vaccines within WHO EUL\/PQ Evaluation Process, WHO."},{"key":"ref_70","first-page":"1","article-title":"Inactivated vaccines: A promising old tool against COVID-19","volume":"4","author":"Iglesias","year":"2020","journal-title":"Res. Rev. Insights"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S1473-3099(21)00020-7","article-title":"Inactivated COVID-19 vaccines to make a global impact","volume":"21","author":"Iversen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/biologics1030020","article-title":"Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena","volume":"1","author":"Chavda","year":"2021","journal-title":"Biologics"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"787881","DOI":"10.3389\/fbioe.2021.787881","article-title":"Circular RNA: Biosynthesis in vitro","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","article-title":"Circular RNA vaccines against SARS-CoV-2 and emerging variants","volume":"185","author":"Qu","year":"2022","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.cell.2022.03.009","article-title":"Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","article-title":"Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management","volume":"26","author":"Chavda","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Dhama, K., Dhawan, M., Tiwari, R., Emran, T.B., Mitra, S., Rabaan, A.A., Alhumaid, S., Alawi, Z.A., and Al Mutair, A. (2022). COVID-19 intranasal vaccines: Current progress, advantages, prospects, and challenges. Hum. Vaccin Immunother., 1\u201311.","DOI":"10.1080\/21645515.2022.2045853"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e160921191568","DOI":"10.2174\/1871526521666210218201113","article-title":"Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control","volume":"21","author":"Ejtahed","year":"2021","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/jmv.26769","article-title":"SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice","volume":"93","author":"He","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Westendorf, K., \u017dentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., and Pustilnik, A. (2022). LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv.","DOI":"10.1016\/j.celrep.2022.110812"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Dougan, M., Azizad, M., Chen, P., Feldman, B., Frieman, M., Igbinadolor, A., Kumar, P., Morris, J., Potts, J., and Baracco, L. (2022). Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv.","DOI":"10.1101\/2022.03.10.22272100"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"109869","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","article-title":"Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.it.2020.09.004","article-title":"Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions","volume":"41","author":"Gavor","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Cathcart, A.L., Havenar-Daughton, C., Lempp, F.A., Ma, D., Schmid, M.A., Agostini, M.L., Guarino, B., Di iulio, J., Rosen, L.E., and Tucker, H. (2022). The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv.","DOI":"10.1101\/2021.03.09.434607"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Levin, M.J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., and Levinson, D.J. (2022). Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for Prevention of COVID-19. N. Engl. J. Med., 386.","DOI":"10.1056\/NEJMoa2116620"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/ofid\/ofab466.1646","article-title":"LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab\/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults","volume":"8","author":"Levin","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Fenwick, C., Turelli, P., Ni, D., Perez, L., Lau, K., Lana, E., Pellaton, C., Raclot, C., Esteves-Leuenberger, L., and Campos, J. (2022). SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties. bioRxiv.","DOI":"10.1101\/2022.03.18.484873"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Su, S.-C., Yang, T.-J., Yu, P.-Y., Liang, K.-H., Chen, W.-Y., Yang, C.-W., Lin, H.-T., Wang, M.-J., Lu, R.-M., and Tso, H.-C. (2021). Structure-guided antibody cocktail for prevention and treatment of COVID-19. PLoS Pathogens, 17.","DOI":"10.1371\/journal.ppat.1009704"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12929-021-00777-9","article-title":"Antibody cocktail effective against variants of SARS-CoV-2","volume":"28","author":"Liang","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Ku, Z., Xie, X., Lin, J., Gao, P., El Sahili, A., Su, H., Liu, Y., Ye, X., Li, X., and Fan, X. (2022). Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth. bioRxiv.","DOI":"10.1101\/2022.02.01.478504"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Zhang, C., and Yang, M. (2022). Antimicrobial Peptides: From Design to Clinical Application. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030349"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"731828","DOI":"10.3389\/fphar.2021.731828","article-title":"Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics","volume":"12","author":"Basit","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s42003-021-01736-8","article-title":"Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection","volume":"4","author":"Karoyan","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4155\/fmc-2020-0262","article-title":"De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence","volume":"13","author":"Bung","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Farooq, S., and Ngaini, Z. (2020). Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). Chem. Afr., 1\u201313.","DOI":"10.1007\/s42250-020-00203-x"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acsinfecdis.1c00070","article-title":"Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2","volume":"7","author":"Bojadzic","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1001\/jama.2020.22240","article-title":"Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"324","author":"Self","year":"2020","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_116","first-page":"e21360","article-title":"A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study","volume":"35","author":"Wang","year":"2021","journal-title":"FASEB J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ddr.21679","article-title":"Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19","volume":"81","author":"Rothlin","year":"2020","journal-title":"Drug Dev. Res."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Mahoney, M., Damalanka, V.C., Tartell, M.A., Chung, D.H., Lourenco, A.L., Pwee, D., Mayer Bridwell, A.E., Hoffmann, M., Voss, J., and Karmakar, P. (2021). A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. bioRxiv.","DOI":"10.1101\/2021.05.06.442935"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gendis.2020.06.007","article-title":"Known drugs and small molecules in the battle for COVID-19 treatment","volume":"7","author":"Panoutsopoulos","year":"2020","journal-title":"Genes Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1021\/acs.jpcb.0c07312","article-title":"Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations","volume":"124","author":"Nguyen","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41401-021-00735-z","article-title":"Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"109957","DOI":"10.1016\/j.mehy.2020.109957","article-title":"Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?","volume":"144","author":"Haggag","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijid.2021.05.055","article-title":"Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study","volume":"108","author":"Umemura","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00210-020-02034-6","article-title":"Chloroquine\/hydroxychloroquine: An inflammasome inhibitor in severe COVID-19?","volume":"394","author":"Bahadoram","year":"2021","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"104228","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.eclinm.2020.100645","article-title":"Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe COVID-19","volume":"29","author":"Omrani","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.eclinm.2021.100773","article-title":"Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial","volume":"33","author":"Johnston","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"639108","DOI":"10.3389\/fcimb.2021.639108","article-title":"CRISPR\/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases","volume":"11","author":"Ding","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"198282","DOI":"10.1016\/j.virusres.2020.198282","article-title":"CRISPR systems: Novel approaches for detection and combating COVID-19","volume":"294","author":"Safari","year":"2021","journal-title":"Virus Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"743580","DOI":"10.3389\/fmicb.2021.743580","article-title":"Potential Use of CRISPR\/Cas13 Machinery in Understanding Virus\u2013Host Interaction","volume":"12","author":"Bayoumi","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sjbs.2021.10.020","article-title":"A review of COVID-19: Treatment strategies and CRISPR\/Cas9 gene editing technology approaches to the coronavirus disease","volume":"29","author":"Ullah","year":"2022","journal-title":"Saudi. J. Biol. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-021-01030-2","article-title":"Compact RNA editors with small Cas13 proteins","volume":"40","author":"Kannan","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1038\/s41596-019-0210-2","article-title":"SHERLOCK: Nucleic acid detection with CRISPR nucleases","volume":"14","author":"Kellner","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Joung, J., Ladha, A., Saito, M., Segel, M., Bruneau, R., Huang, M.W., Kim, N.G., Yu, X., Li, J., and Walker, B.D. (2020). Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv.","DOI":"10.1101\/2020.05.04.20091231"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41551-021-00760-7","article-title":"CRISPR-based diagnostics","volume":"5","author":"Kaminski","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"110754","DOI":"10.1016\/j.mehy.2021.110754","article-title":"A one-step platform for screening high-efficient and minimal off-target CRISPR\/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients","volume":"159","author":"Li","year":"2022","journal-title":"Med. Hypotheses"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Dixon, B.E., Wools-Kaloustian, K., Fadel, W.F., Duszynski, T.J., Yiannoutsos, C., Halverson, P.K., and Menachemi, N. (2020). Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. medRxiv.","DOI":"10.1101\/2020.10.11.20210922"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Calabrese, C., Garofalo, E., Bruni, A., Vatrella, A., and Pelaia, G. (2021). Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063059"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Fetta, S., and Kontoghiorghe, C.N. (2021). Conventional and Unconventional Approaches for Innovative Drug Treatments in COVID-19: Looking Outside of Plato\u2019s Cave. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22137208"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11010-020-03935-z","article-title":"SARS-CoV-2 mediated lung inflammatory responses in host: Targeting the cytokine storm for therapeutic interventions","volume":"476","author":"Asrani","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1177\/0300060518800588","article-title":"Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer","volume":"46","author":"Feng","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Gritti, G., Raimondi, F., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Mic\u00f2, C., and Fagiuoli, S. (2020). IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: An observational cohort study. medRxiv.","DOI":"10.1101\/2020.04.01.20048561"},{"key":"ref_148","unstructured":"Investigators, T.R.-C., and Derde, L.P.G. (2021). Effectiveness of Tocilizumab, Sarilumab, and Anakinra for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial. medRxiv."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40290-020-00342-z","article-title":"IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?","volume":"34","author":"Atal","year":"2020","journal-title":"Pharm. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e9533","DOI":"10.7717\/peerj.9533","article-title":"Small molecule therapeutics for COVID-19: Repurposing of inhaled furosemide","volume":"8","author":"Wang","year":"2020","journal-title":"PeerJ"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.amjms.2020.05.044","article-title":"Is Inhaled Furosemide a Potential Therapeutic for COVID-19?","volume":"360","author":"Brennecke","year":"2020","journal-title":"Am. J. Med. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:47Z","timestamp":1760138447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":151,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23116083"],"URL":"https:\/\/doi.org\/10.3390\/ijms23116083","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}